Munsat T L, Taft J, Kasdon D
Neurol Clin. 1987 Feb;5(1):159-70.
Thyrotropin releasing hormone (TRH) has potential therapeutic applications in amyotrophic lateral sclerosis (ALS) and related diseases because of its function as a neuroregulator of the anterior horn cell. However, its therapeutic potential, and that of other neuropeptides, is reduced by the blood-brain barrier that limits access to neuronal cells. We have thus explored the direct intrathecal administration of TRH in ALS, with both short-term boluses and infusions and chronic constant infusions. Our experience suggests that this approach is safe, has high patient acceptance, and is worthy of more careful evaluation.
促甲状腺激素释放激素（TRH）因其作为前角细胞的神经调节因子的功能，在肌萎缩侧索硬化症（ALS）及相关疾病中具有潜在的治疗应用价值。然而，其治疗潜力以及其他神经肽的治疗潜力，因血脑屏障限制了对神经元细胞的作用而降低。因此，我们探索了在ALS中直接鞘内注射TRH，包括短期推注和输注以及长期持续输注。我们的经验表明，这种方法是安全的，患者接受度高，值得更仔细的评估。
